Background: Lymph node metastasis with extranodal extension represents one of the most important adverse prognostic factors for survival in patients with head and neck squamous cell carcinoma. We propose that extranodal extension occurs to differing extents. The aim of this study was to determine the prognostic significance of extranodal extension in patients with head and neck squamous cell carcinoma. Methods: Two hundred and ninety-eight patients with head and neck squamous cell carcinoma who underwent surgical resection and neck dissection were included. Cervical lymph nodes were classified into four categories: (i) pathological N negative, (ii) extranodal extension negative, (iii) non-surgical extranodal extension and (iv) surgical extranodal extension. Results: Lymph node metastases were detected in 67.1% of laryngeal/hypopharyngeal cancer patients and 52.7% of oral cancer patients. The 3-year disease-specific survival rates for patients in the pathological N negative, extranodal extension negative, non-surgical extranodal extension and surgical extranodal extension groups were 90.9%, 79.6%, 63.8% and 48.3%, respectively. In laryngeal/hypopharyngeal cancer patients, surgical extranodal extension was associated with a significantly poorer disease-specific survival than a pathological N negative, extranodal extension negative or non-surgical extranodal extension status. In oral cancer patients, no significant differences were observed between the non-surgical and surgical extranodal extension groups. However, non-surgical extranodal extension was associated with a poorer disease-specific survival than a pathological N negative or extranodal extension negative status. Conclusions: Surgical extranodal extension was a poor prognostic factor in patients with head and neck squamous cell carcinoma. The prognostic significance of surgical extranodal extension differed between laryngeal/hypopharyngeal and oral cancer patients. The clinical significance of surgical extranodal extension was much greater for patients with laryngeal/hypopharyngeal cancer than oral cancer.
Introduction
By the time a diagnosis is established, 50.0% of head and neck squamous cell carcinoma (HNSCC) patients will have metastatic disease in the cervical lymph nodes (LNs) (1, 2) . The presence of LN metastasis (LNM) is considered to be one of the most important adverse prognostic factors (3) . In addition, the detection of extranodal extension (ENE) further decreases survival rates and is associated with increased rates of regional recurrence and distant metastasis (4) (5) (6) . The Radiation Therapy Oncology Group 9501 (7) and European Organization for Research and Treatment of Cancer 22931 (8) clinical trials indicated that ENE is an important criterion for the use of adjuvant chemotherapy in addition to radiotherapy. Moreover, combined analysis (9) of data from these two clinical trials (7, 8) revealed that ENE was one of only two factors, with microscopically involved margins being the other, that warranted postoperative concurrent chemoradiotherapy (CCRT). However, postoperative CCRT is a high-intensity treatment that can lead to complications in some patients. In Japan, many HNSCC patients are elderly and may not tolerate such treatment. Therefore, the use of postoperative CCRT requires consideration of individual patients on a case-by-case basis and precise identification of those patients who could benefit from such treatment.
We propose that ENE can occur to varying extents. Therefore, patients in which the HNSCC extends to the capsule only, or spreads beyond the capsule to a distance that is determined only under microscopic examination, should not have the same prognosis as patients with gross invasion through the capsule into surrounding connective tissue that necessitates resection during surgery. The purpose of this study was to evaluate the prognostic significance of ENE in patients with HNSCC. Patients were classified according to their LNM status. We determined the prognostic significance of that classification in each primary site.
Materials and methods

Patients
Between 2007 and 2015, 298 patients with previously untreated HNSCC, including laryngeal cancer (LC)/hypopharyngeal cancer (HPC) (n = 167) and oral cancer (OC) (n = 131), who underwent treatment with curative intent, were identified from the case records of the National Cancer Center Hospital (Tokyo, Japan). All participants provided informed written consent. The retrospective design of the study was approved by the National Cancer Center Ethics Committee (2013-247). Research was conducted in accordance with the Declaration of Helsinki, as revised in 1983.
After the patients' initial assessment, all major management decisions were made at a multidisciplinary team meeting of surgical and radiation oncologists. The treatment strategy was based on several factors, including patient preference, radiation-related morbidity and general performance status. All patients in this study underwent surgical resection of the primary tumor and neck dissection that was performed by a multidisciplinary team comprising head and neck surgeons, plastic reconstructive surgeons and general surgeons. Exclusion criteria included prior therapy for upper digestive tract malignancies and primary lesions with positive surgical margins.
The baseline characteristics of the patients are summarized in Table 1 . Of the 298 patients enrolled in this study, 167 (56.0%) had LC/HPC and 131 (44.0%) had OC. Two hundred and forty-two patients (81.2%) were male and 56 patients (18.8%) were female. The median age at presentation was 67.0 (range, 22.0-92.0) years.
The median follow-up duration was 36.0 months for surviving patients. In LC patients, the primary tumor site was the glottis in 20 patients, supraglottis in 6 patients and subglottis in 2 patients. In HPC patients, the primary tumor site was the pyriform sinus in 93 patients, posterior wall in 25 patients and postcricoid in 11 patients. In OC patients, the primary tumor site was the tongue in 70 patients, lower gingiva in 22 patients, oral floor in 20 patients, buccal mucosa in 14 patients, upper gingiva in 4 patients and hard palate in one patient.
Neck dissection
In LC/HPC, it is our policy to dissect Levels II-IV in patients with clinically N0 necks and to dissect Levels II-V in patients with N positive necks. In OC, it is our policy to perform elective neck dissection of Levels I-III in patients with clinically N0 necks and to perform comprehensive neck dissection of Levels I-V in patients with N positive necks. The necessity of resecting adjacent tissues (e.g. the internal jugular vein, sternocleidomastoid muscle, or deep cervical muscle) was determined preoperatively at a team meeting by referring to imaging studies or neck lymph node palpation.
Statistical analyses
Cervical LNs were classified into four categories according to LNM status: (i) no evidence of LNM (pathological N [pN] negative); (ii) no evidence of ENE (ENE negative); (iii) ENE detected by pathological examination (non-surgical ENE); or (iv) ENE that required resection of adjacent tissues, such as the internal jugular vein, sternocleidomastoid muscle, or deep cervical muscle (surgical ENE). None of the patients had LN invasion of the carotid artery. In all LNs with surgical ENE, ENE was confirmed microscopically. Survival analyses were performed using the Kaplan-Meier method and survival curves were compared using the log-rank test. A P < 0.05 was considered statistically significant.
Results
Extranodal extension
Two hundred and ninety-eight patients were enrolled in the study. Pathological examination detected LNMs in 67.1% of LC/HPC patients (n = 112) and 52.7% of OC patients (n = 69). The LNM statuses were as follows: ENE negative (n = 47; 42.0%), non-surgical ENE (n = 20; 17.8%), and surgical ENE (n = 45; 40.2%) in LC/HPC patients and ENE negative (n = 38; 55.1%), non-surgical ENE (n = 11; 15.9%) and surgical ENE (n = 20; 29.0%) in OC patients (Table 2) .
ENE was found to correlate with the number of positive LNs. In LC/HPC patients, ENE was evident in 42.9% (n = 9 patients) with one positive LN (non-surgical ENE, 14.3% [n = 3 patients]; surgical ENE, 28.6% [n = 6 patients]), 61.1% (n = 22 patients) with 2-3 positive LNs (non-surgical ENE, 22.2% [n = 8 patients]; surgical ENE, 38.9% [n = 14 patients]), and 81.0% (n = 34 patients) with >3 positive LNs (non-surgical ENE, 21.4% [n = 9 patients]; surgical ENE, 59.5% [n = 25 patients]). In OC patients, ENE was evident in 20.0% (n = 5 patients) with one positive LN (non-surgical ENE, 8.0% [n = 2 patients]; surgical ENE, 12.0% [n = 3 patients]), 50.0% (n = 15 patients) with 2-3 positive LNs (non-surgical ENE, 20.0% [n = 6 patients]; surgical ENE, 30.0% [n = 9 patients]), and 78.6% (n = 11 patients) with >3 positive LNs (non-surgical ENE, 21.5% [n = 3 patients]; surgical ENE, 57.1% [n = 8 patients]) ( Table 3 ).
Tumor recurrence
In the 64 patients with LC/HPC who experienced recurrence (38.3%), the sites of recurrence were as follows: local recurrence only (n = 7 patients; 10.9%), regional LNM only (n = 29 patients; 45.3%), pulmonary metastasis only (n = 24 patients; 37.5%), local recurrence and regional LNM (n = 1 patient; 1.6%), and regional LN and pulmonary metastasis (n = 3 patients; 4.7%). In the 50 patients with OC who experienced recurrence (38.2%), the sites of recurrence were as follows: local recurrence only (n = 17 patients; 34.0%), regional LNM only (n = 21 patients; 42.0%), pulmonary metastasis only (n = 6 patients; 12.0%), local recurrence and regional LNM (n = 2 patients; 4.0%), local recurrence and pulmonary metastasis (n = 1 patient; 2.0%), regional LN and pulmonary metastasis (n = 2 patients; 4.0%), and local recurrence and regional LN and pulmonary metastasis (n = 1 patient; 2.0%). The mean time to locoregional recurrence and distant metastasis was 12.1 (range, 1.0-87.0) and 13.2 (range, 1.0-53.0) months, respectively (P > 0.05).
Survival analyses
The time from surgery to evaluation ranged from 1.0 to 120.0 months with a median follow-up duration of 36.0 months for surviving patients. The 3-year overall survival and disease-specific survival (DSS) rates of patients in the LC/HPC and OC groups were 72.5% and 77.4% and 71.8% and 73.2%, respectively (Fig. 1A  and B) .
Kaplan-Meier curves of DSS for HNSCC patients stratified according to their LNM status are depicted in Fig. 2A-C . The 3-year DSS rate for all patients combined was 90.9%. The 3-year DSS rates for patients in the pN negative, ENE negative, non-surgical ENE and surgical ENE groups were 90.9%, 79.6%, 63.8% and 48.3%, respectively. No statistically significant differences were observed between patients in the non-surgical and surgical ENE groups. However, statistically significant differences were observed between all other groups. In LC/HPC patients, surgical ENE was associated with a significantly poorer DSS compared with a pN negative neck (P < 0.001) and an ENE negative or non-surgical ENE status (P < 0.05). However, no statistically significant differences were observed between patients in the non-surgical ENE and pN negative or ENE negative groups. In contrast, in OC patients, no statistically significant differences were observed between the non-surgical and surgical ENE groups. Patients with a non-surgical ENE status were associated with a significantly poorer DSS compared with patients in the pN negative or ENE negative groups (P < 0.05).
Adjuvant treatment
Adjuvant treatment was performed according to the following postoperative histopathological findings: surgical margin status, cervical LN status and ENE status. Postoperative treatments and treatment modalities according to primary site and LNM status are summarized in Table 4 . Overall, a higher proportion of patients with surgical ENE underwent postoperative treatment compared with patients with non-surgical ENE.
Discussion
Identifying a potential subgroup of HNSCC patients with a poor prognosis may help to determine those patients who are most likely to benefit from concurrent adjuvant therapies, while minimizing morbidity. Although the molecular biology of tumors has advanced in recent decades, the traditional clinical and pathological characteristics of the tumor still play an important role in predicting tumor behavior.
The presence or absence of LNM is considered to be one of the most important prognostic factors for survival in HNSCC patients. When ENE of the LNs is present, further reductions in survival have been described (10) . ENE is defined as the expansion of the tumor beyond the LN capsule. There is evidence in the literature to suggest that patients who have LNM with ENE have a poorer prognosis than do patients with a tumor that is limited to the LN (11-15). Dünne et al. (11) conducted a meta-analysis of 9 studies to determine the prognostic significance of ENE in 2573 patients with HNSCC. The authors concluded that the presence of ENE in the neck dissections had a negative impact on survival (summarized odds ratio: 2.7, 95.0% confidence interval: 2.2−3.4) (11). Thus, ENE is widely regarded as a pathological marker of a poor prognosis in patients with HNSCC (11) (12) (13) (14) (15) (16) .
A number of studies (11, 17, 18) have suggested that a carcinoma, which infiltrates and spreads beyond the LN capsule, represents a more aggressive disease that is related to the genetic nature of the tumor cell or to the pathological compliance of the hosts' immune system rather than a late presentation. Several studies have also reported on the importance of differing extents of ENE that is associated with a poor prognosis. Patients in which the carcinoma extends to the capsule only or spreads beyond the capsule to a distance that is determined only under microscopic examination should not have the same prognosis as patients with gross invasion through the capsule into surrounding connective tissue. In the present study, patients who had LNM with non-surgical ENE had a significantly poorer DSS than ENE negative patients with LNM. In contrast, DSS did not differ between non-surgical and surgical ENE patients. When patients were classified according to primary tumor site, there was no difference between LC/HPC patients with an ENE negative and non-surgical ENE status and a surgical ENE status was associated with a significantly poorer DSS. However, DSS was significantly poorer in non-surgical ENE compared with ENE negative patients and the same negative impact on DSS was observed between OC patients with a non-surgical and surgical ENE status. In OC, previous studies (19, 20) have reported that even microscopic ENE is of critical importance and no statistically significant differences in survival were detected with respect to the extent of ENE. In contrast, a study conducted on 170 HNSCC patients with LC/HPC (21) demonstrated that the risks of recurrence and death are higher when macroscopic ENE is evident. When the tumor was confined to the LN or exhibited microscopic invasion beyond the capsule, there were no statistically significant differences in risk rates (21) . Our study corroborates these findings. The difference in the prognostic significance of surgical ENE may be explained by the difference in the biological properties of the tumor. OC appears to cause lymphatic spread easier than LC/HPC.
In the present study, the indications for adjuvant treatment were maintained throughout the study period. Patients with ENE positive LNs were considered candidates for postoperative CCRT. However, among the 96 patients with ENE, only 49 patients (51.0%) underwent postoperative treatment and, of these, only 22 patients (44.9%) received postoperative CCRT. Some patients were not treated with postoperative CCRT because of their advanced age, comorbidities, or refusal. Some patients were treated with postoperative adjuvant radiotherapy only due to their poor medical condition or refusal of other approaches. According to the findings of the Radiation Therapy Oncology Group 9501 (7) and European Organization for Research and Treatment of Cancer 22931 (8) clinical trials, patients who have LNM with ENE are candidates for postoperative CCRT. However, postoperative CCRT is a highintensity treatment that can lead to complications in some patients and may be considered inappropriate for patients with multiple comorbidities (22) . In the long-term findings of the Radiation Therapy Oncology Group 91-11 clinical trial (23) there was an unexplained increase in non-cancer-related deaths in patients who received cisplatin-based CCRT. Therefore, the use of postoperative CCRT for individual patients requires careful consideration. ENE occurs to varying extents. It is detected by postoperative pathological examination or is apparent prior to or during surgery and requires resection of adjacent tissues, such as the internal jugular vein, sternocleidomastoid muscle, or deep cervical muscle. In addition, the prognostic significance of ENE differs between each primary site. We propose that distinguishing between these ENE statuses as prognostic factors is warranted and should be evaluated according to primary site, as well as, the human papillomavirus. Surgical ENE is identified during surgery. Therefore, decisions regarding postoperative treatment strategies can be made earlier after surgery; thus, eliminating the need to wait for the final pathological report. In our study, it is suggested that the prognostic significance of surgical ENE for patients with LC/HPC is important.
Our findings were influenced by the retrospective design of the study, including the lack of a randomized patient population and associated biases. In our study, the LC/HPC group included a greater proportion of patients with advanced-stage disease than the OC group. Patients with early-stage LC/HPC were treated with definitive radiotherapy. In contrast, patients with OC were treated with surgery even in early-stage disease. In addition, adjuvant treatments were variable. Since the efficacy of adjuvant treatments is beyond the scope of this study, we do not discuss them here. In addition to pathological findings, the LNM status identified during surgery, which is associated with a poor prognosis, may assist in determining those patients who would benefit most from postoperative CCRT, whilst minimizing morbidity. A clear direction for future investigation would be to attempt to classify patients according to the extent of LNM. Furthermore, the prognostic significance of these LNM statuses should be investigated prospectively in each primary site to clarify the indication of postoperative CCRT.
Conclusions
Surgical ENE that requires resection of adjacent tissues (except adipose tissue) was identified as a poor prognostic factor of survival in HNSCC patients. The prognostic significance of surgical ENE differed between LC/HPC and OC patients. The clinical significance of surgical ENE was much greater for patients with LC/HPC than OC. Further studies are required to clarify the role of postoperative CCRT in the management of this subgroup of patients.
